#Switzerland #Diabetes Care #CGM System #Basel #FiberSense

FiberSense Achieves CE Mark for Continuous Glucose Monitoring System

In a significant regulatory milestone, FiberSense AG has announced that its Continuous Glucose Monitoring (CGM) system has successfully received CE marking under EU regulation 2017/745, classifying it as a Class IIb medical device. This accomplishment is not only a critical step towards commercializing the product but also signals the beginning of a larger vision for multi-marker health monitoring.

The Innovation Behind FiberSense CGM

The FiberSense CGM system stands out for its innovative optical sensor technology, designed to continuously monitor blood sugar levels and glucose trends in adults with diabetes. By measuring glucose concentrations in the interstitial fluid just beneath the skin, the system provides crucial insights for users to manage their glucose levels effectively in everyday life.

This user-friendly device emphasizes practicality; it features a maintenance-free optical sensor and an adhesive overlay that can be worn for up to 28 days before replacement. Moreover, the detector is cleverly designed to be rechargeable and reusable, catering to the needs of those who seek an effortless yet effective diabetes management solution.

Market Readiness and Future Aspirations

According to Michael Tillmann, the Chairman and CEO of FiberSense, this certification marks a pivotal moment for the company. After years of rigorous development, they are now shifting their focus towards production scaling and commercialization. Preliminary orders are already on the books, with initial shipments expected by the end of 2026.

The successful attainment of CE marking has prompted FiberSense to enter an exciting new stage of development. Not only is this CGM system the inaugural regulated application of their optical sensing technology, but it also lays the groundwork for a broader platform strategy, termed CxM (Continuous Metabolic Monitoring). The company envisions extending their monitoring capabilities to track other metabolic and lifestyle health parameters, such as ketones, lactate, and cortisol, pending necessary technical, clinical, and regulatory validations.

A Step Towards Comprehensive Health Monitoring

The FiberSense CGM system is more than just a glucose measuring device; it represents a step forward in the evolving landscape of health technology. As the healthcare community increasingly recognizes the importance of continuous monitoring, FiberSense is well-positioned to play a vital role in this transition.

With its emphasis on user-friendly design and reliable performance, FiberSense aims to empower individuals living with diabetes to gain better control over their health. As the company prepares to launch this groundbreaking product, the anticipation surrounding its potential impact is palpable.

For more information about FiberSense and its CGM system, visit their official site at www.fibersense-cxm.com. The future of metabolic monitoring may very well be on the horizon, thanks to innovations like that of FiberSense.

About FiberSense

Headquartered in Basel, Switzerland, FiberSense AG specializes in optical biomarker sensing technology focused on health and medical applications. With roots tracing back to EyeSense, a spin-off of CIBA Vision (formerly part of Novartis), FiberSense combines expertise in optical sensors with the ambition to develop innovative monitoring solutions that seamlessly fit into active lifestyles.

For media inquiries, please contact:
+49 (0)6026 942 121
[email protected]